Inclusion Criteria:

• Measurable unresectable Stage III or Stage IV melanoma
• ECOG Performance Status 0 or 1
• 4 weeks or greater since treatment
• Must have recovered from any acute toxicity associated with prior therapy
• Life expectancy of greater than 12 weeks
• 18 years of age or older
• Laboratory values as outlined in protocol
• Negative screening tests for HIV, active Hepatitis B and Hepatitis C
• Patients who received prior therapy with anthracyclines should have a baseline MUGA or echo with a normal ejection fraction

Exclusion Criteria:

• CNS metastases
• Pregnant or nursing women
• Prior therapy with bevacizumab or ipilimumab
• Active infection
• Autoimmune disease: Patients with a history of inflammatory bowel disease are excluded from this study as are patients with a history of symptomatic autoimmune disease
• Any other malignancy from which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix
• Any underlying medical condition which, in the principal investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of adverse events
• Any concurrent medical condition requiring the use of systemic steroids
• Inadequately controlled hypertension
• Any prior history of hypertensive crisis or hypertensive encephalopathy
• NYHA Grade II or greater congestive heart failure
• History of myocardial infarction or unstable angina within 6 months prior to study enrollment
• History of stroke of transient ischemic attack within 6 months prior to study enrollment
• Significant known vascular disease
• Symptomatic peripheral vascular disease
• Evidence of bleeding diathesis or coagulopathy
• Major surgical procedure or significant traumatic injury within 28 days prior to study enrollment
• Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
• History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment
• Serious, non-healing wound, ulcer or bone fracture
• Proteinuria at screening
• Known hypersensitivity to any component of bevacizumab
• History of hemoptysis within 3 months prior to study enrollment
• Current, ongoing treatment with full-dose warfarin or its equivalent
• Current or recent (within 10 days of enrollment) use of aspirin (>325mg/day) or chronic use of other NSAIDs
• Medications that inhibit platelet function
• Known involvement of melanoma within gastrointestinal tract
• Ulcerated skin lesions